X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Canadian companies complete handover of drugs rights

Content Team by Content Team
4th January 2019
in Manufacturing, Middle East and South Asia, News, Packaging & Logistic
Canadian companies complete handover of drugs rights

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Nuvo Pharmaceuticals has acquired the rights covering more than 20 drugs from fellow Canadian company Aralez Pharmaceuticals.

With the deal, announced by Nuvo on Monday, December 31, Nuvo now owns Aralez’s Canadian speciality pharmaceutical business. This unit includes anti-inflammatory drug Cambia (diclofenac potassium), which is under licence from Depomed, as well as Blexten (bilastine), an antihistamine, licensed from Faes Farma.

Aralez’s pharma business also includes the Canadian distribution rights to Resultz (isopropyl myristate), a head lice treatment, which it licenses from Piedmont Pharmaceuticals.

Nuvo said this part of the deal will allow the company to acquire and launch additional commercial products in Canada.

Nuvo has also acquired the worldwide rights and royalties from licensees for arthritis drug Vimovo (naproxen and esomeprazole magnesium) and Yosprala (aspirin and omeprazole), a treatment for reducing the risk of further heart problems in people with such difficulties, among other things.

In August 2018, the companies announced that they were in talks on the potential acquisition.

In the recent announcement, Nuvo confirmed that the agreed payment to Aralez is $110 million less a $4.4 million deposit previously paid “and subject to certain working capital and indebtedness adjustments”.

Jesse Ledger, Nuvo’s president and CEO, said that the close of the transaction “positions Nuvo as one of the premier speciality pharmaceutical companies in Canada”.

In its own statement, Aralez explained that after deciding to sell its main operating businesses, the company conducted a court-supervised sale and auction process as part of independent Canadian and US restructuring proceedings. The Ontario Superior Court of Justice and the US Bankruptcy Court ultimately approved the sales to Nuvo in December 2018.

Financing for the acquisition was provided by Deerfield Management Company, which has offices in the US, China and Switzerland.

Previous Post

FDA approves Roches Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

Next Post

Bristol-Myers Squibb to acquire Celgene in $74bn deal

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Bristol-Myers Squibb to acquire Celgene in $74bn deal

Bristol-Myers Squibb to acquire Celgene in $74bn deal

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In